SCUEL — Japan healthcare data

HomeTherapeutic areas › Antispasmodics

Japan market screening · Therapeutic class

Antispasmodics in Japan

鎮けい剤 · Japan Standard Commodity Classification

12 molecules in this class are marketed in Japan across 51 products. 9 of those products are not shipping normally today — 17.6% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.

12Molecules
51Marketed products
9Products constrained

Molecules in this class

Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.

MoleculeProducts CompaniesConstrained Supply mix
Eperisone Hydrochlorideエペリゾン塩酸塩1093
Tizanidine Hydrochlorideチザニジン塩酸塩871
Atropine Sulfate Hydrateアトロピン硫酸塩水和物76
Baclofenバクロフェン73
Scopolamine Butylbromideブチルスコポラミン臭化物541
Scopolia Extractロートエキス444
Flopropioneフロプロピオン31
Timepidium Bromide Hydrateチメピジウム臭化物水和物32
Afloqualoneアフロクアロン11
Magnesium Sulfate Hydrate硫酸マグネシウム水和物11
Papaverine Hydrochlorideパパベリン塩酸塩11
Piperidolate Hydrochlorideピペリドレート塩酸塩11
Normal supply Limited supply Supply suspended

How to read this

Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.

Screening this area in Japan?

Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.

Send an enquiry

Our Database Division replies in English within three business days (Japan time).